Takeda Pharmaceuticals agreed in May 2026 to pay $13,670,921 to resolve False Claims Act (“FCA”) allegations tied to its Trintellix speaker program. This was not a one-off.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results